EPOCH Trial

If you are interested in learning more about the EPOCH clinical trial, please contact your doctor.

The purpose of the EPOCH trial is to determine if addition of TheraSphere® to standard-of-care second-line chemotherapy improves survival time and is safe.25,26

Eligible participants for this trial are patients with metastatic colorectal cancer (mCRC) of the liver who:
  • Have disease progression with first-line chemotherapy with either an oxaliplatin- or irinotecan-based regimen; and
  • Are scheduled to receive second-line chemotherapy with the alternate chemotherapy regimen.

The trial will involve approximately 340 patients at up to 100 sites worldwide, including North America, Europe, and Asia.25,26

Principal Investigators:
  • Mary Mulcahy, MD  Northwestern University, Chicago, US
  • Ricky Sharma, MD   Oxford University, UK